Elanco Animal Health Incorporated
ELANNYSEHealthcare● Active
$23.34
$-0.29(-1.23%)
Market Cap$11.7B
P/E Ratio—
52W High$27.72
52W Low$13.16
Elanco Animal Health Incorporated (ELAN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELAN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.40
Est. $0.35 · +15.7%
Revenue
$1.37B
Est. $1.28B · +7.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
ELAN reports quarterly as a NYSE-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.28 | — | — | — | $1.31B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $0.35 | $0.40 | +15.7% | $1.37B | $1.28B | +7.3% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $0.11 | $0.13 | +18.2% | $1.14B | $1.09B | +4.7% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.13 | $0.19 | +46.1% | $1.14B | $1.09B | +4.1% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.20 | $0.26 | +30.0% | $1.24B | $1.09B | +13.9% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.31 | $0.37 | +19.4% | $1.19B | $1.18B | +1.3% |
| ▼ Q1 FY2025 | Feb 25, 2025 | $0.16 | $0.14 | -12.5% | $1.02B | $1.21B | -15.7% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.12 | $0.13 | +8.3% | $1.03B | $1.01B | +1.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$0.40
EPS Est.
$0.35
EPS Surpr.
+15.7%
Revenue
$1.37B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.13
EPS Est.
$0.11
EPS Surpr.
+18.2%
Revenue
$1.14B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.19
EPS Est.
$0.13
EPS Surpr.
+46.1%
Revenue
$1.14B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.26
EPS Est.
$0.20
EPS Surpr.
+30.0%
Revenue
$1.24B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.37
EPS Est.
$0.31
EPS Surpr.
+19.4%
Revenue
$1.19B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
$0.14
EPS Est.
$0.16
EPS Surpr.
-12.5%
Revenue
$1.02B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.13
EPS Est.
$0.12
EPS Surpr.
+8.3%
Revenue
$1.03B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.25 | $0.25 | $0.26 | 4 |
| Q3 FY2028 | $0.25 | $0.26 | $0.26 | 6 |
| Q2 FY2028 | $0.35 | $0.35 | $0.36 | 4 |
| Q1 FY2028 | $0.43 | $0.44 | $0.45 | 4 |
| Q4 FY2027 | $0.22 | $0.22 | $0.22 | 3 |
| Q3 FY2027 | $0.22 | $0.22 | $0.22 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.3B | $1.3B | $1.3B | 4 |
| Q3 FY2028 | $1.3B | $1.3B | $1.3B | 4 |
| Q2 FY2028 | $1.4B | $1.4B | $1.5B | 5 |
| Q1 FY2028 | $1.5B | $1.5B | $1.5B | 2 |
| Q4 FY2027 | $1.2B | $1.3B | $1.3B | 3 |
| Q3 FY2027 | $1.2B | $1.3B | $1.3B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +15.7% | $22.99 | $26.18 | +13.88% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +18.2% | $24.75 | $26.38 | +6.59% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +46.1% | $22.50 | $21.60 | -4.00% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +30.0% | $13.99 | $16.48 | +17.80% |
| ▲ Q2 FY2025 | May 7, 2025 | +19.4% | $9.51 | $12.01 | +26.29% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -12.5% | $11.11 | $10.70 | -3.69% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +8.3% | $12.86 | $14.50 | +12.75% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +25.0% | $12.38 | $12.99 | +4.93% |
Q2 FY2026+13.88%
Report Date
May 6, 2026
EPS Beat/Miss
+15.7%
Price Before
$22.99
Price After
$26.18
Q1 FY2026+6.59%
Report Date
Feb 24, 2026
EPS Beat/Miss
+18.2%
Price Before
$24.75
Price After
$26.38
Q4 FY2025-4.00%
Report Date
Nov 5, 2025
EPS Beat/Miss
+46.1%
Price Before
$22.50
Price After
$21.60
Q3 FY2025+17.80%
Report Date
Aug 7, 2025
EPS Beat/Miss
+30.0%
Price Before
$13.99
Price After
$16.48
Q2 FY2025+26.29%
Report Date
May 7, 2025
EPS Beat/Miss
+19.4%
Price Before
$9.51
Price After
$12.01
Q1 FY2025-3.69%
Report Date
Feb 25, 2025
EPS Beat/Miss
-12.5%
Price Before
$11.11
Price After
$10.70
Q4 FY2024+12.75%
Report Date
Nov 7, 2024
EPS Beat/Miss
+8.3%
Price Before
$12.86
Price After
$14.50
Q3 FY2024+4.93%
Report Date
Aug 8, 2024
EPS Beat/Miss
+25.0%
Price Before
$12.38
Price After
$12.99
Avg Beat Reaction+11.18%
Avg Miss Reaction-3.69%
Beat Rate7 / 8 quarters
Largest Move+26.29% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELAN ends December
Elanco Animal Health Incorporated (ELAN) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.40 — beating the analyst consensus of $0.35 by +15.7%. ELAN has beaten EPS estimates for 5 consecutive quarters. The next ELAN earnings date is expected around September 1, 2026.
Each quarter, investors track ELAN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELAN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELAN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELAN earnings · 5 questionsElanco Animal Health Incorporated's next earnings report is expected around September 1, 2026. ELAN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELAN historically reports after market close (AMC).
ELAN earnings datewhen is ELAN earningsELAN next earnings datewhen does ELAN report earningsELAN earnings calendar
▸ Source: FMP · Elanco Animal Health Incorporated SEC filings · US GAAP · Elanco Animal Health Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026